Biodefence vaccines - BioSante/USAMRIID

Drug Profile

Biodefence vaccines - BioSante/USAMRIID

Alternative Names: Anthrax vaccine - BioSante/USAMRIID; Biodefense vaccines - BioSante/USAMRIID; Plague vaccine - BioSante/USAMRIID; Ricin vaccine - BioSante/USAMRIID; Staphylococcus aureus vaccine - BioSante/USAMRIID

Latest Information Update: 30 Jul 2013

Price : $50

At a glance

  • Originator BioSante Pharmaceuticals; United States Army Medical Research Institute of Infectious Diseases
  • Developer ANI Pharmaceuticals
  • Class Anthrax vaccines; Bacterial vaccines; Plague vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anthrax; Ricin poisoning; Staphylococcal infections; Yersinia infections

Most Recent Events

  • 18 Jul 2013 Discontinued - Preclinical for Yersinia infections in USA (unspecified route)
  • 18 Jul 2013 Discontinued - Phase-I/II for Staphylococcal infections in USA (unspecified route)
  • 18 Jul 2013 Discontinued - Phase-I/II for Ricin poisoning in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top